AKESO(HK:09926) 智通财经网·2025-09-01 09:33Core Viewpoint - The report from Credit Lyonnais indicates a target price increase for Kangfang Biotech (09926) from HKD 112.6 to HKD 177, maintaining an outperform rating [1] Sales Forecast - The company is expected to achieve a year-on-year sales growth of 33.7% in the first half of 2025, which aligns with market expectations [1] - Sales forecasts for Kangfang Biotech for 2025 to 2027 have been revised upward by 1.2%, 5.1%, and 18.9% respectively [1] Profit Forecast - Net profit estimates for the fiscal years 2026 and 2027 have been increased by 10.9% and 35% respectively [1] Clinical Results - The overall survival (OS) analysis results for AK112 are statistically significant and clinically meaningful, providing positive reference for the overseas HARMONi trial [1]